Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of an ischemia injury include bradycardia, headache, hypertension, and seizures. Ischemia-reperfusion injury is associated with serious clinical manifestations, including myocardial hibernation, acute heart failure, cerebral dysfunction, gastrointestinal dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. Ischemia-reperfusion injury is a critical medical condition that poses an important therapeutic challenge for physicians.
Market Dynamics
Increasing number of research and development activities by the key market players for the treatment of patients suffering from reperfusion injury is expected to drive the growth of market over the forecast period. For instance, on May 31, 2022, GNT Pharma, a pharmaceutical company,reported that Nelonemdaz is under clinical for phase I clinical trial. Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction.
Furthermore, in September 2021, GNT Pharma, a pharmaceutical company, reported that the Korea Ministry of Food and Drug Safety (MFDS) had approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is based on the encouraging results of GNT Pharma’s earlier phase II trials. The outcomes of this phase III study will be instrumental in documenting the therapeutic potential of nelonemdaz as an effective treatment for acute ischemic stroke.
Key features of the study:
- This report provides an in-depth analysis of the global ischemia reperfusion injury therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Revive Therapeutics Ltd., Faraday Pharmaceuticals, Abiomed, Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global Ischemia Reperfusion Injury Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ischemia reperfusion injury therapeutics market
Detailed Segmentation:
- Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment:
- Drug Therapy
- Medicated Gas
- Others (Vitamin Therapy and among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type:
- Heart Injury
- Kidney Injury
- Intestine Injury
- Other Injury (Brain Injuries and Among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By End user:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others(Academic and Research Institutes and among Others)
- Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Revive Therapeutics Ltd.
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.
